XNSE
LASA
Market cap5mUSD
Nov 12, Last price
10.68INR
Name
Lasa Supergenerics Ltd
Chart & performance
P/E
—
P/S
2.13
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.27%
Rev. gr., 5y
-34.11%
Revenues
251m
-82.35%
Net income
-341m
L+131.00%
CFO
-81m
L+185.70%
Dividend
Sep 16, 20220.25 INR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
Key people
Omkar Herlekar
Chairman of the Board, Managing Director
Varsha Joshi
Chief Financial Officer · since 2024
Mitti Jain
Compliance Officer, Company Secretary · since 2025
Shivanand Hegde
Whole-time Director
Umesh Pawar
Whole-Time Director · since 2025
Manali Bhagtani
Non-Executive Independent Director · since 2018
Pravin Lachake
Non-Executive Independent Director · since 2025
Ketan Songal
Non-Executive Independent Director · since 2025
Hardesh Tolani
Non-Executive Independent Director
Yogesh Ughada
Non-Executive Independent Director · since 2025
Rekha Wakh
Non-Executive Independent Director · since 2025
Valuation
Title INR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||